SCHEDULE: Oramed Pharmaceuticals Discloses 9.9% Stake in Scilex

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Co.

Summary

• Oramed Pharmaceuticals Inc. (the "Reporting Person") has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Scilex Holding Co.
• The filing indicates Oramed Pharmaceuticals Inc. beneficially owns 833,473 shares of Scilex Holding Co. common stock.
• This ownership represents 9.9% of Scilex Holding Co.'s class of securities.
• The beneficially owned shares are comprised of common stock issuable upon the exercise of warrants, which are exercisable within 60 days of the filing date.
• The percentage of class is calculated based on 7,585,446 shares of Common Stock outstanding as of November 3, 2025, plus the 833,473 shares from warrants.
• Oramed Pharmaceuticals Inc. has sole voting power and sole dispositive power over all 833,473 shares.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Scilex Holding Co.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently conveys positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's or reporting person's future performance or strategic plans.

Management Comments

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc., certified that, to the best of his knowledge and belief, the information set forth in the statement is true, complete, and correct.
• Management also certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant ownership stake by one pharmaceutical company (Oramed) in another (Scilex), which is a common occurrence in the biotechnology and pharmaceutical sectors, often signaling strategic investments or potential collaborations, though this filing does not specify the underlying strategic intent beyond beneficial ownership.

Stakeholder Impact

• Shareholders of Scilex Holding Co. are informed of a significant beneficial owner, Oramed Pharmaceuticals Inc., holding a 9.9% stake.
• This disclosure provides transparency regarding the ownership structure and potential influence of a large institutional holder.

Key Dates

Keywords

Oramed Pharmaceuticals, Scilex Holding Co, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Equity Stake, Pharmaceuticals, Biotechnology